In: NEOPLASMA, vol. 54, no. 5
E. Faber - V. Koza - A. Vítek - J. Mayer - P. Sedlacek - P. Žák - J. Zapletalová - K. Benešová - H. Krejcova - K. I. - P. Cetkovský
Detaily:
Rok, strany: 2007, 443 - 446
O článku:
Allogeneic stem cell transplantation (AlloSCT) has been currently recommended in the treatment of patients with chronic
myeloid leukemia (CML) as a second option after imatinib failure or in selected group of patients with high-risk CML and
low risk for transplant-related mortality. The actual role of reduced-intensity conditioning (RIC) before AlloSCT in CML
patients has not been yet conclusively established. The Czech National Hematopoietic Stem Cell Transplantation Registry
has conducted a retrospective analysis of all patients (n=29) transplanted after RIC from the Registry database containing
295 patients with CML transplanted in the Czech Republic in years 1988-2005 and compared them with patients at comparable
age (median age 48.3 and 50.6 years, respectively; p=0.587) transplanted during the same period of time using conventional
myeloablative conditioning (n=26). Survival advantage of patients transplanted after RIC has been confirmed by log rank
test (p=0.036) despite the fact that the relapse rate was significantly higher in RIC group (44.8% versus 0%). Both groups
did not differ significantly in the use of voluntary unrelated donors, type of the grafts and in incidence of acute graft versus
host disease (GVHD). However, there were trends for higher risk of CML and higher use of unrelated donors in the
myeloablative group while peripheral stem cell grafts and chronic GVHD were observed more frequently in the RIC group.
Transplant-related mortality was the leading cause of death in both groups of patients. Our results should be interpreted with
caution because they may be influenced by small groups of subjects and also the impact of patients with high EBMT risk
score on inferior survival in the myeloablative group cannot be fully eliminated. More retrospective and prospective studies
are needed to elucidate the actual role of RIC before AlloSCT for CML.
Key words: allogeneic stem cell transplantation, chronic myeloid leukemia, reduced-intensity conditioning, imatinib
Ako citovať:
ISO 690:
Faber, E., Koza, V., Vítek, A., Mayer, J., Sedlacek, P., Žák, P., Zapletalová, J., Benešová, K., Krejcova, H., I., K., Cetkovský, P. 2007. Reduced-intensity conditioning for allogeneic stem cell transplantation
in patients with chronic myeloid leukemia is associated with better overall
survival but inferior disease-free survival when compared with myeloablative
conditioning – a retrospect. In NEOPLASMA, vol. 54, no.5, pp. 443-446. 0028-2685.
APA:
Faber, E., Koza, V., Vítek, A., Mayer, J., Sedlacek, P., Žák, P., Zapletalová, J., Benešová, K., Krejcova, H., I., K., Cetkovský, P. (2007). Reduced-intensity conditioning for allogeneic stem cell transplantation
in patients with chronic myeloid leukemia is associated with better overall
survival but inferior disease-free survival when compared with myeloablative
conditioning – a retrospect. NEOPLASMA, 54(5), 443-446. 0028-2685.